# A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

> **NCT05535244** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 90 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Cevostamab
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT05535244
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-17
- **Primary completion:** 2027-02-26
- **Final completion:** 2027-02-26
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05535244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05535244, "A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT05535244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*